Exagen Inc. XGN
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +41.28%
- 1 year
- -26.96%
- Open
- 8.58
- Prev close
- 8.70
- Mkt cap
- 208.10M
- Vol
- 394.01K
- Avg vol
- 370.26K
- EPS
- -0.81
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.28
- High
- 8.61
- Forward P/E
- -5.96
- Beta
- 1.35
- Short ratio
- 3.12
- Inst. own
- 57.22%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 5, 2024
- 50-d avg
- 3.59
- 200-d avg
- 2.50
- 1y target
- 6.25
News
3 days ago globenewswire.com
Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen will participate in the Canaccord Genuity MedTech & Diagnostics Conference November 11 and the Craig-Hallum Alpha Select Conference November 17
5 days ago globenewswire.com
Exagen to Announce Third Quarter Financial Results on November 10, 2026
CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30,…
1 week ago defenseworld.net
Exagen (NASDAQ: XGN) owner buys 14,000 shares in new insider filing
What happened Exagen Inc. (NASDAQ: XGN) filed a Form 4 showing Jorey Chernett, a director and 10% owner, bought 14,000 common shares on 2026-10-19. The filing lists the trade as a purchase, and the…
1 week ago defenseworld.net
Exagen (NASDAQ:XGN) CEO John Aballi Sells 34,294 Shares of Stock
Exagen Inc. (NASDAQ: XGN - Get Free Report) CEO John Aballi sold 34,294 shares of the company's stock in a transaction on Friday, October 16th. The stock was sold at an average price of $7.87, for a…
-
1 week ago benzinga.com
Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $9 to $11.
-
2 weeks ago benzinga.com
TD Cowen Maintains Buy on Exagen, Raises Price Target to $11
TD Cowen analyst Dan Bergstrom maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $10 to $11.
1 month ago defenseworld.net
Universal Health Services (NYSE:UHS) versus Exagen (NASDAQ:XGN) Financial Analysis
Universal Health Services (NYSE: UHS - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two…
1 month ago defenseworld.net
Exagen Inc. (NASDAQ:XGN) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Exagen Inc. (NASDAQ: XGN - Get Free Report) has earned an average rating of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat Ratings reports. One research…
1 month ago benzinga.com
Full Transcript: Exagen Q2 2026 Earnings Call
On Tuesday, Exagen (NASDAQ:XGN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive…
1 month ago defenseworld.net
InfuSystem (NYSE:INFU) & Exagen (NASDAQ:XGN) Head to Head Contrast
Exagen (NASDAQ: XGN - Get Free Report) and InfuSystem (NYSE: INFU - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies…
1 month ago defenseworld.net
Exagen (NASDAQ:XGN) versus Gaxos.ai (NASDAQ:GXAI) Financial Review
Exagen (NASDAQ: XGN - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses…
2 months ago defenseworld.net
Exagen Inc. (NASDAQ:XGN) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Exagen Inc. (NASDAQ: XGN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat reports. One…
2 months ago defenseworld.net
Reviewing Amplifon (OTCMKTS:AMFPF) & Exagen (NASDAQ:XGN)
Amplifon (OTCMKTS:AMFPF - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the…
-
2 months ago benzinga.com
B. Riley Securities Reiterates Buy on Exagen, Raises Price Target to $12
B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $12.
2 months ago marketbeat.com
Exagen Q2 Earnings Call Highlights
Exagen NASDAQ: XGN reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to…
2 months ago seekingalpha.com
Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript
Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 415.3% to $18.81 during Tuesday's regular session. The company's market cap stands at $1.9 million. Adagio Medical Holdings (NASDAQ:ADGM) shares…
2 months ago zacks.com
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings…
-
2 months ago benzinga.com
Exagen Raises FY2026 Sales Guidance from $70.000M-$73.000M to $72.000M-$75.000M vs $71.560M Est
Exagen (NASDAQ:XGN) raises FY2026 sales outlook from $70.000 million-$73.000 million to $72.000 million-$75.000 million vs $71.560 million estimate.
2 months ago globenewswire.com
Exagen Inc. Reports Second Quarter 2026 Financial Results
Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 -…
3 months ago globenewswire.com
Exagen Inc. to Participate in Upcoming Investor Conference
CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor…
3 months ago globenewswire.com
Exagen to Announce Second Quarter Financial Results on August 4, 2026
CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026,…
-
4 months ago benzinga.com
Roth Capital Initiates Coverage On Exagen with Buy Rating, Announces Price Target of $8
Roth Capital analyst Max Masucci initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and announces Price Target of $8.
-
5 months ago benzinga.com
Exagen Announces Publication Of New Systematic Review Demonstrating That AVISE Lupus Algorithm Delivers Superior Diagnostic Accuracy And Consistency Across Patient Populations Compared With Conventional Serologic Tests Alone
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markersDemonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier,…
5 months ago globenewswire.com
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier,…
5 months ago zacks.com
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the…
5 months ago seekingalpha.com
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
5 months ago marketbeat.com
Exagen Q1 Earnings Call Highlights
Exagen NASDAQ: XGN reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician…
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
5 months ago benzinga.com
Exagen Affirms FY2026 Sales Guidance of $70.000M-$73.000M vs $71.267M Est
Exagen (NASDAQ:XGN) affirms FY2026 sales outlook from $70.000 million-$73.000 million to $70.000 million-$73.000 million vs $71.267 million estimate.
-
5 months ago benzinga.com
Exagen Q1 EPS $(0.17) Beats $(0.23) Estimate, Sales $17.306M Beat $16.414M Estimate
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.23) by 26.09 percent. This is a 15 percent increase over losses of $(0.20) per…
-
7 months ago benzinga.com
Canaccord Genuity Maintains Buy on Exagen, Lowers Price Target to $10
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $15 to $10.
-
7 months ago benzinga.com
Craig-Hallum Maintains Buy on Exagen, Lowers Price Target to $10
Craig-Hallum analyst John Wilkin maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $12 to $10.
-
7 months ago benzinga.com
Keybanc Maintains Overweight on Exagen, Lowers Price Target to $10
Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and lowers the price target from $15 to $10.
7 months ago benzinga.com
4 Analysts Have This To Say About Exagen
4 Analysts Have This To Say About Exagen
-
7 months ago benzinga.com
Exagen Q4 EPS $(0.20) Misses $(0.18) Estimate, Sales $16.631M Beat $16.567M Estimate.
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent. This is unchanged from the same period last year. The…
-
7 months ago benzinga.com
Earnings Scheduled For March 10, 2026
Earnings Scheduled For March 10, 2026
-
8 months ago benzinga.com
TD Cowen Maintains Buy on Exagen, Lowers Price Target to $10
TD Cowen analyst Dan Brennan maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $13 to $10.
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
9 months ago benzinga.com
B. Riley Securities Reiterates Buy on Exagen, Lowers Price Target to $8
B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $18 to $8.
-
12 months ago benzinga.com
B. Riley Securities Reiterates Buy on Exagen, Raises Price Target to $18
B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and raises the price target from $15 to $18.
-
12 months ago benzinga.com
CORRECTION: Exagen Q3 Adj. EPS $(0.19) Misses $(0.16) Estimate, Sales $17.244M Beat $16.895M Estimate
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 20.25 percent. This is a 32.14 percent increase over losses of $(0.28) per…
-
12 months ago benzinga.com
Exagen Affirms FY2025 Sales Guidance of $65.000M-$70.000M vs $67.487M Est
Exagen (NASDAQ:XGN) affirms FY2025 sales outlook from $65.000 million-$70.000 million to $65.000 million-$70.000 million vs $67.487 million estimate.
12 months ago benzinga.com
Earnings Scheduled For November 4, 2025
Earnings Scheduled For November 4, 2025
1 year ago benzinga.com
Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday